LPAR1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
5031439C20, AI326300, EDG 2, Endothelial differentiation gene 2, Endothelial differentiation, lysophosphatidic acid G protein coupled receptor, 2, GPCR 26, Gpcr91, Kdt2, LPA receptor 1, LPA receptor EDG2, LPA-1, LPAR1_HUMAN, Lysophosphatidic acid receptor 1, Lysophosphatidic acid receptor Edg-2, MGC105279, MGC29102, Mrec1.3, Ventricular zone gene 1, rec.1.3, vzg-1
LPAR1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type A549 cell line (ab288558). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
EDG2 also known as LPA-1 LPAR1 or lysophosphatidic acid receptor 1 acts as a receptor for LPA (lysophosphatidic acid) a bioactive lipid mediator. This protein has a molecular mass of approximately 41 kDa. It is part of the G protein-coupled receptor (GPCR) family. EDG2 is mainly expressed in organs such as the brain heart and lungs. It plays an important role in cellular signal transduction by binding LPA which leads to various cellular responses.
EDG2/LPA-1 influences several cellular processes including cell proliferation migration and survival. It does not function as part of a larger complex; instead it activates intracellular signaling cascades upon LPA binding. This activation leads to downstream effects that regulate processes like cytoskeletal reorganization and gene expression. Its influence extends to immune response modulation making it significant in understanding cellular behavior and communication.
EDG2/LPA-1 is important in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K/AKT) signaling pathways. These pathways affect cell growth survival and metabolism showcasing the receptor's importance in cellular regulation. Through these pathways EDG2 interacts with multiple proteins including RAC1 a small GTPase involved in cytoskeletal organization and various kinase enzymes that facilitate signal transduction.
EDG2/LPA-1 has associations with cancer and fibrosis. In cancer the receptor influences tumor growth and metastasis due to its role in cell migration and proliferation. It connects to the matrix metalloproteinases (MMPs) in this context which degrade extracellular matrix components to facilitate cancer cell invasion. Additionally in fibrotic diseases EDG2's influence on fibroblast activity leads to tissue scarring and dysfunctional repair. Understanding these connections helps to explore therapeutic targets meant to modulate EDG2/LPA-1 activity in pathological conditions.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
73 bp deletion after Asn137 of the WT protein.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com